CKD subgroup: subdivided by those with and without proteinuria) mostly stage 3, some early 4. reduced NYHA class: Mixed Funded by industry CIBIS-II trial: Castagno ) Intervention 1: Beta- blockers (BB). Bisoprolol dose increased progressively to 10mg daily according to tolerance. Placebo. average (mean) N = 1119 patients with CKD Subgroup analysis of older trialb HF: LVEF 35% or less. Symptoms corresponding to class III or IV of the New York Heart Association (NYHA). Stability during the preceding 6 weeks. Cardiovascular therapy including a diuretic and ACE inhibitor. CKD subgroup: Two strata eGFR 45-59, stage eGFR ~20a Mortality Hospitalisation Recruitment dates not reported. 43% of patients in trial had Subgroup status: Ejection fraction: All reduced NYHA class: Class III or IV Industry funded MERIT-HF trial: Ghali (MERIT-HF group ) Intervention 1: Beta- blockers (BB). Metoprolol CR/XL. target dose of 200mg daily. Placebo. Duration 1 year N=1469 patients with CKD Post-hoc subgroup analysis of older trialb HF: aged 40-80 y, HF class II-IV, ejection fraction <40% taking ACE-I unless not tolerated and diuretics. CKD subgroup: Two strata eGFR 45 to 60, eGFR <45, class Mortality Hospitalisation 98. 37% of patients in trial had CKD (12% Subgroup status: Ejection fraction: All reduced NYHA class: Mixed Funded by industry Chronic Heart Failure Treating Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 Study Intervention and comparison Population Outcomes Comments SENIORS trial: Cohen- (Flather ) Intervention 1: Beta- blockers (BB). Nebivolol initial target of 10mg once daily Placebo. Duration mean 21 (SD 9) months. N=704 patients with CKD Post-hoc subgroup analysis of multicentre trial of elderly patients HF: Aged 70 years or over. 